|
TERF2IP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.99760216648792E-15 |
| Normal-vs-Stage2 |
4.61409999996665E-06 |
| Normal-vs-Stage3 |
1.22124532708767E-15 |
| Normal-vs-Stage4 |
1.87150295261063E-12 |
| Stage1-vs-Stage2 |
2.994200E-01 |
| Stage1-vs-Stage3 |
1.841500E-03 |
| Stage1-vs-Stage4 |
5.816700E-03 |
| Stage2-vs-Stage3 |
5.337000E-03 |
| Stage2-vs-Stage4 |
7.897200E-03 |
| Stage3-vs-Stage4 |
7.868400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.18829999999648E-05 |
| Normal-vs-Asian |
1.63619999993259E-07 |
| Caucasian-vs-AfricanAmerican |
2.455200E-01 |
| Caucasian-vs-Asian |
1.612270E-02 |
| AfricanAmerican-vs-Asian |
6.623800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.63402624764331E-12 |
| Male-vs-Female |
1.816770E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62803104331033E-12 |
| Normal-vs-Age(41-60Yrs) |
9.73177094465427E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62547753035369E-12 |
| Normal-vs-Age(81-100Yrs) |
1.90988999999586E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.338400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.202800E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.597800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.119800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.134000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.703400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.433320E-04 |
| Classical-VS-Follicular |
3.101400E-01 |
| Classical-VS-Other |
6.393400E-01 |
| Classical-VS-Normal |
1.62525548574877E-12 |
| Tall-VS-Follicular |
5.61289999999603E-05 |
| Tall-VS-Other |
1.353400E-01 |
| Tall-VS-Normal |
1.65445435129641E-12 |
| Follicular-VS-Other |
4.973600E-01 |
| Follicular-VS-Normal |
1.97890000053214E-07 |
| Other-VS-Normal |
7.828200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.13082892944294E-14 |
| Normal-vs-N1 |
2.88270518566947E-11 |
| N0-vs-N1 |
1.941170E-01 |
|
|
